
1. south med j. 2004 apr;97(4):364-73; quiz 374.

hepatitis c infection: clinical review.

pearlman bl(1).

author information: 
(1)center hepatitis c, atlanta medical center, atlanta, ga 30312, usa.
brianpearlman@hotmail.com

nearly three million persons united states viremic hepatitis c
(hcv). despite decreasing incidence hcv country, prevalence of
hcv-related chronic liver disease increasing. infections united
states acquired intravenous drug use. chronicity rate hcv high, 
reaching 85% populations, risk progression advanced liver
disease high 20% within twenty years infection. host factors like
alcohol use accelerate rate progression. enzyme immunoassay the
preferred initial test diagnosis; third generation assay greater than
a 99% specificity immunocompetent patients. barring contraindications, the
standard care treatment chronic hcv become pegylated interferon and
ribavirin. therapy, cure rate treatment-na√Øve patients about
55%, rates higher certain groups. common side effects therapy
include neuropsychiatric symptoms, influenza-like symptoms hematological
abnormalities.

doi: 10.1097/01.smj.0000118903.35704.30 
pmid: 15108830  [indexed medline]

